DaVita Inc. 2023 Form 10-K Summary
Business context and reporting period
Annual report for the fiscal year ended December 31, 2023, compared primarily with 2022. DaVita provides U.S. dialysis and related laboratory services, integrated kidney care (IKC), ancillary services, and international dialysis services. U.S. dialysis generated about 89% of consolidated revenue.
- At year-end, U.S. operations included 2,675 outpatient centers serving approximately 200,800 patients; international operations included 367 centers in 11 countries serving about 49,400 patients.
- IKC served approximately 58,000 patients in risk-based arrangements and a further 17,000 in other integrated care arrangements.
Financial and operating results
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $12.14 billion | $11.61 billion |
| Operating income | $1.60 billion | $1.34 billion |
| Net income attributable to DaVita | $691.5 million | $560.4 million |
| Diluted earnings per share | $7.42 | $5.85 |
| Cash from operating activities | $2.06 billion | $1.56 billion |
| Free cash flow (company-defined) | $1.24 billion | $817 million |
- Revenue increased 4.6%; operating income increased 19.7%. Approximate operating margin rose to 13.2% from 11.5%. Net income attributable to DaVita increased about 23%.
- U.S. dialysis revenue grew 3.2% to $10.94 billion, primarily from a $12.20 increase in average patient service revenue per treatment to $377.44. Treatments declined 0.2%; normalized non-acquired treatment growth was negative 0.1%.
- U.S. dialysis operating income rose 13.4% to $1.78 billion. Patient-care costs per treatment increased 1.0% to $255.78.
- Ancillary revenue grew 18.0% to $1.30 billion. IKC revenue rose 35.2% to $511 million, including $55 million of incremental shared-savings revenue from lifting certain recognition constraints. Ancillary operations recorded a $9 million operating loss, improved from a $97 million loss in 2022.
- Debt expense increased to $399 million from $357 million; the weighted-average effective interest rate on all debt was 4.52%, versus 3.96% in 2022.
- At December 31, cash and cash equivalents were $380 million, short-term investments were $12 million, and long-term debt carrying value was $8.27 billion. Debt principal outstanding was $8.45 billion. The company reported $1.5 billion of undrawn revolving-credit capacity and stated that liquidity should cover obligations for the foreseeable future, including the next 12 months.
Material changes versus 2022
- Improved operating results reflected higher average revenue per treatment, lower pharmaceutical costs and contract wages, improved collections, and growth in IKC and international operations. These gains were partly offset by higher compensation, severance, center-closure, legal, and IKC support costs.
- Operating cash flow increased $494 million, supported by improved operating results and collections. Accounts receivable days outstanding fell to 54 from 66.
- DaVita repurchased 2.90 million shares for $286 million, compared with 8.09 million shares for $788 million in 2022. The share count declined 1.8% year over year.
- The company refinanced its prior term loan and revolving facility, establishing a $1.25 billion Term Loan A-1 and a revolving facility of up to $1.5 billion. It also entered forward interest-rate cap agreements intended to limit rate exposure through 2026.
- U.S. dialysis centers decreased by a net 49, largely reflecting closures and optimization; international centers increased by 17.
Outlook, risks, contingencies, and unusual items
- For 2024, management expects treatment volumes to return to positive growth as the cumulative COVID-19 impact on patient mortality and census subsides. It expects adjusted operating income to improve, citing billing-cycle improvements and cost-saving initiatives, while anticipating continued wage and other cost pressure. The filing provides no specific numerical earnings or revenue guidance.
- U.S. dialysis center closure costs were approximately $99 million in 2023; management expects elevated closure levels to continue in 2024. Severance costs were also recorded. These items affect reported operating income; adjusted operating income is a non-GAAP measure.
- A $26.1 million goodwill impairment was recorded for the transplant software business, reflecting missed revenue targets and lower future expectations. A $7.7 million gain from reducing estimated earn-out obligations partly offset the impact.
- A $40 million charge was recorded for a legal matter in corporate administrative support; the company also disclosed a $40 million reserve for the 2017 U.S. Attorney investigation. Other investigations and litigation remain unresolved, and outcomes and potential losses may be difficult to estimate.
- Key business risks include reliance on higher-paying commercial insurance, reimbursement and regulatory changes, labor and supply inflation, competition, lower patient growth or elevated mortality, execution of IKC and home-dialysis strategies, cybersecurity and data privacy, and substantial debt and interest-rate exposure.
- Commercial payors represented 33% of U.S. dialysis patient service revenue, while government programs represented 67%. Management states that commercial rates generate nearly all U.S. dialysis profits, making payer mix and commercial contract terms especially significant.
- Other commitments include supplier minimum-purchase agreements, potential partnership put obligations, and up to $300 million of contingent consideration tied to Mozarc milestones during 2024–2028; $86 million was recorded for that obligation at year-end.
Important facts for investors to verify
- Review the 2024 treatment-volume and adjusted-operating-income trajectory against management’s outlook, including patient census and mortality trends.
- Track commercial-insurance mix, realized reimbursement rates, payer contract renewals, and the effects of Medicare and state policy changes.
- Assess whether labor, supply, severance, and center-closure costs are contained and whether cost-saving initiatives deliver the expected benefits.
- Review the status and potential financial consequences of the Colorado and New Jersey investigations, California insurance inquiry, and other disclosed proceedings; the filing does not provide a clear estimate of total possible losses.
- Monitor debt maturities, interest expense, leverage, and liquidity, as well as potential partnership put payments and Mozarc milestone obligations.
- Consider the uncertainty in dialysis revenue estimates: management generally expects estimation risk within 1% of U.S. dialysis revenue, which it says could represent about 6% of that business’s adjusted operating income.